Novartis acquires rights to new broad-spectrum antibiotic

Novartis has acquired rights to a new broad-spectrum antibiotic currently in Phase 2 development in connection with its takeover of the product’s owner, Protez Pharmaceuticals of Malvern, Pennsylvania.